IP Library Granted Patent US 8,022,098
Granted Patent B2
US 8,022,098 · App. 12/713,605 · Granted Sep 20, 2011

Deuterated aminocyclohexyl ether compounds and processes for preparing same

Assignee: Cardiome Pharma Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,022,098
App. No.
12/713,605
Granted
Sep 20, 2011
Kind
B2
Abstract

This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same.

Claims (90)

1. A method of treating arrhythmia in a human, wherein the method comprises administering to the human in need thereof a therapeutically effective amount of a compound of formula (I):

wherein:

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently hydrogen or deuterium; and

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

where at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 is deuterium or at least one of R 9 and R 10 is —OCD 3 ;

or an isolated stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein the deuterium present in the compound is present at greater than the natural abundance of deuterium.

2. The method of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

3. The method of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

4. The method of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

5. The method of claim 1 wherein:

R 1 and R 2 are both deuterium;

R 3 and R 4 are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

6. The method of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 is —OCD 3 ;

R 10 is hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

7. The method of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 is hydroxy, methoxy or —OCD 3 ;

R 10 is —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

8. The method of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is deuterium;

R 12 and R 13 are both hydrogen or are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

9. The method of claim 1 wherein:

R 1 and R 2 are both hydrogen or are both deuterium;

R 3 and R 4 are both hydrogen or are both deuterium;

R 5 and R 6 are both hydrogen or are both deuterium;

R 7 and R 8 are both hydrogen or are both deuterium;

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

R 11 is hydrogen or deuterium;

R 12 and R 13 are both deuterium; and

R 14 , R 15 , and R 16 are all hydrogen or all deuterium.

10. A method of treating arrhythmia in a human, wherein the method comprises administering to the human in need thereof a therapeutically effective amount of a compound of formula (II):

wherein

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 and R 13 are each independently hydrogen or deuterium; and

R 9 and R 10 are each independently hydroxy, methoxy or —OCD 3 ;

where at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 is deuterium or at least one of R 9 and R 10 is —OCD 3 ;

or an isolated stereoisomer thereof;

or a pharmaceutically acceptable salt thereof;

wherein the deuterium present in the compound is present at greater than the natural abundance of deuterium.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: CHOU, DOUG TA HUNG; PLOUVIER, BERTRAND M.C.; PANG, PETER; YEE, JAMES GEE KEN; WHEELER, JEFFREY JEROME; YIFRU, AREGAHEGN S.; DAVIDOFF, ALLEN W.
To: CARDIOME PHARMA CORP.
Reel/Frame 052085/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CARDIOME PHARMA CORP.
To: CORREVIO CANADA CORP.
Reel/Frame 046831/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CORREVIO CANADA CORP.
To: CORREVIO INTERNATIONAL SÀRL
Reel/Frame 046831/0227 →
RELEASE OF SECURITY INTEREST Recorded Jun 20, 2016
From: MIDCAP FINANCIAL TRUST
To: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
Reel/Frame 038961/0202 →
SECURITY INTEREST Recorded Jul 24, 2014
From: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
To: MIDCAP FUNDING V, LLC
Reel/Frame 033407/0314 →
Continuity (9)
Division 11581225 · Oct 13, 2006
Continuation In Part 11455280 · Jun 15, 2006
Continuation In Part PCTUS2006023668 · Jun 15, 2006
Continuation In Part PCTUS2005011124 · Mar 31, 2005
Provisional Application 60748248 · Dec 7, 2005
Provisional Application 60690989 · Jun 15, 2005
Provisional Application 60559405 · Apr 1, 2004
Provisional Application 60586992 · Jul 8, 2004
Related Publication 20100152276A1 · Jun 17, 2010